Latest News
-
NEWTON, Mass. — Karyopharm Therapeutics Inc. (OTC Pink: KPTIQ) (“Karyopharm” or the “Company”), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for XPOVIO® (selinexor) in combination with ruxolitinib for patients with myelofibrosis....
-
STOCKHOLM, Sweden – Sobi® today announced that the European Commission (EC) has approved Tryngolza™ (olezarsen) as an adjunct to diet, in combination with other lipid-lowering therapies, for the treatment of adult patients with severe hypertriglyceridaemia (sHTG, fasting triglyceride levels of ≥880 mg/dL [≥10 mmol/L]). Tryngolza is the first and only...
-
REDWOOD CITY, Calif. — Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced publication of a peer-reviewed case report in ESMO Rare Cancers, regarding...
